Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Role of the chemokine eotaxin in the pathogenesis of equine sweet itch.

Benarafa C, Collins ME, Hamblin AS, Cunningham FM.

Vet Rec. 2002 Dec 7;151(23):691-3.

PMID:
12503787
3.

Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration.

White JR, Lee JM, Dede K, Imburgia CS, Jurewicz AJ, Chan G, Fornwald JA, Dhanak D, Christmann LT, Darcy MG, Widdowson KL, Foley JJ, Schmidt DB, Sarau HM.

J Biol Chem. 2000 Nov 24;275(47):36626-31.

4.

Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications.

Amerio P, Frezzolini A, Feliciani C, Verdolini R, Teofoli P, De Pità O, Puddu P.

Curr Drug Targets Inflamm Allergy. 2003 Mar;2(1):81-94. Review.

PMID:
14561178
5.

Evidence for increased expression of eotaxin and monocyte chemotactic protein-4 in atopic dermatitis.

Taha RA, Minshall EM, Leung DY, Boguniewicz M, Luster A, Muro S, Toda M, Hamid QA.

J Allergy Clin Immunol. 2000 May;105(5):1002-7.

PMID:
10808183
6.

Eotaxin and asthma.

Pease JE, Williams TJ.

Curr Opin Pharmacol. 2001 Jun;1(3):248-53. Review.

PMID:
11712747
7.

Chemokine receptor usage by human eosinophils. The importance of CCR3 demonstrated using an antagonistic monoclonal antibody.

Heath H, Qin S, Rao P, Wu L, LaRosa G, Kassam N, Ponath PD, Mackay CR.

J Clin Invest. 1997 Jan 15;99(2):178-84.

8.
9.

Human RANTES acts as a receptor antagonist for guinea pig eotaxin in vitro and in vivo.

Marleau S, Griffiths-Johnson DA, Collins PD, Bakhle YS, Williams TJ, Jose PJ.

J Immunol. 1996 Nov 1;157(9):4141-6.

PMID:
8892650
10.
12.

Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis.

Park CW, Lee BH, Han HJ, Lee CH, Ahn HK.

Br J Dermatol. 2005 Jun;152(6):1173-81.

PMID:
15948978
13.

Eotaxin and the attraction of eosinophils to the asthmatic lung.

Conroy DM, Williams TJ.

Respir Res. 2001;2(3):150-6. Epub 2001 Mar 29. Review.

14.

Characterisation of the biological activity of recombinant equine eotaxin in vitro.

Benarafa C, Collins ME, Hamblin AS, Sabroe I, Cunningham FM.

Cytokine. 2002 Jul 7;19(1):27-30.

PMID:
12200110
15.

Cloning of equine chemokines eotaxin, monocyte chemoattractant protein (MCP)-1, MCP-2 and MCP-4, mRNA expression in tissues and induction by IL-4 in dermal fibroblasts.

Benarafa C, Cunningham FM, Hamblin AS, Horohov DW, Collins ME.

Vet Immunol Immunopathol. 2000 Oct 31;76(3-4):283-98.

PMID:
11044560
16.

Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma.

Kleinhans M, Tun-Kyi A, Gilliet M, Kadin ME, Dummer R, Burg G, Nestle FO.

Blood. 2003 Feb 15;101(4):1487-93. Epub 2002 Sep 26.

PMID:
12393570
17.
18.

Detection of mRNA for eotaxin-2 and eotaxin-3 in human dermal fibroblasts and their distinct activation profile on human eosinophils.

Dulkys Y, Schramm G, Kimmig D, Knöss S, Weyergraf A, Kapp A, Elsner J.

J Invest Dermatol. 2001 Apr;116(4):498-505.

19.

Production of the novel C-C chemokine MCP-4 by airway cells and comparison of its biological activity to other C-C chemokines.

Stellato C, Collins P, Ponath PD, Soler D, Newman W, La Rosa G, Li H, White J, Schwiebert LM, Bickel C, Liu M, Bochner BS, Williams T, Schleimer RP.

J Clin Invest. 1997 Mar 1;99(5):926-36.

20.

Detection of MCP-4 in dermal fibroblasts and its activation of the respiratory burst in human eosinophils.

Petering H, Höchstetter R, Kimmig D, Smolarski R, Kapp A, Elsner J.

J Immunol. 1998 Jan 15;160(2):555-8.

Supplemental Content

Support Center